71368-80-4 Usage
Description
8-Bromo-1-methyl-6-phenyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine, commonly known as Bromazolam, is a novel benzodiazepine that was first synthesized in 1976 but never marketed. It has gained attention as a designer drug and was first identified by the EMCDDA in Sweden in 2016. Structurally, Bromazolam is similar to traditional benzodiazepines like alprazolam (with a bromine replacing the chlorine) and bromazepam (with the addition of a triazole ring). Although it is not explicitly scheduled, it shares classification with alprazolam and bromazepam as Schedule IV substances in the United States.
Uses
Used in Pharmaceutical Research:
8-Bromo-1-methyl-6-phenyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine is used as a research compound for studying its antianxiety, antidepressant, and psychotropic properties for the central nervous system. Its structural similarity to established benzodiazepines makes it a valuable candidate for investigating potential therapeutic applications and understanding its mechanism of action.
Used in Central Nervous System Applications:
In the field of central nervous system treatments, 8-Bromo-1-methyl-6-phenyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine is used as a potential anxiolytic and sedative agent. Its effects are attributed to its ability to interact with the GABA receptor, similar to traditional benzodiazepines, which can help alleviate anxiety and promote relaxation.
Synthesis
The synthesis of?Bromazolam is as follows：A solution of 1 (1 g, 3.07 mmol of 7-bromo-5-phenyl-1,4-benzodiazepine-2-one) in dry THF (20 mL) was cooled in an ice-water bath and a 60% dispersion of sodium hydride (152.2 mg) was added in one portion. After 20 minutes, di-4-morpholinylphosphinic chloride (943.9 mg, 4.76 mmol) was added at 0° C. and this was stirred for 30 minutes and allowed to warm to room temperature (Ning, R Y., et al., (1976) J Org Chem 41: 2724-2727). The mixture was stirred for 1.5 hours. To this mixture was then added a solution of acetylhydrazide (521.9 mg, 7.14 mmol) in dry butanol (5 mL) and stirring was continued at room temperature for 10 min. The solvents were evaporated and the residue was dissolved in butanol (10 mL) and heated to reflux for 5 hours. Butanol was removed under reduced pressure and the residue was partitioned between CH2Cl2?(50 mL) and water (50 mL). The water layer was extracted by CH2Cl2?(3×30 mL). The combined organic layer was washed by brine (30 mL). The organic layer was dried (Na2SO4) and the solvent was removed under vacuum. The residue was purified by flash chromatography (silica gel) to provide pure 8 [539.5 mg (40% yield)] as a white solid.
Check Digit Verification of cas no
The CAS Registry Mumber 71368-80-4 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 7,1,3,6 and 8 respectively; the second part has 2 digits, 8 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 71368-80:
(7*7)+(6*1)+(5*3)+(4*6)+(3*8)+(2*8)+(1*0)=134
134 % 10 = 4
So 71368-80-4 is a valid CAS Registry Number.
71368-80-4Relevant articles and documents
Stereospecific anxiolytic and anticonvulsant agents with reduced muscle-relaxant, sedative-hypnotic and ataxic effects
-
Page/Page column 29-30, (2008/06/13)
The present invention provides compositions and methods of using stereospecific benzodiazepine derivatives, their salts and prodrugs for the treatment of anxiolytic or convulsant disorders having the side effects of reduced alcohol craving in human alcoholics and a concomitant reduced sedative, hypnotic, muscle relaxant and ataxic side-effects. The invention further provides pharmaceutical compositions for treatment of anxiolytic and convulsant disorders in subjects in need thereof, comprising a compound, prodrug or a salt having a chemical structure represented by any one of Formula I-XXI and a pharmaceutically-acceptable carrier.
This product is a nationally controlled contraband, and the Lookchem platform doesn't provide relevant sales information.